MedTrace Logo

CD8 Minibody Repeatability Study

NCT05744128 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2024-12-03

No results posted yet for this study

Summary

Zr-89 crefmirlimab berdoxam is a Zirconium-89 labelled minibody developed by ImaginAb for full body PET imaging of CD8+ cell distribution (CD8 ImmunoPET). The primary objective of this study is to assess the test-retest repeatability of CD8 immunoPET imaging in oncology patients with stable disease.

Conditions

Interventions

BIOLOGICAL

Zirconium 89Zr crefmirlimab berdoxam

Zirconium-89 labelled minibody for whole body PET imaging to visualize CD8+ cell distribution.

Sponsors & Collaborators

  • University of Hull

    collaborator OTHER

  • ImaginAb, Inc.

    lead INDUSTRY

Principal Investigators

  • Azeem Saleem, MB BS DMRT PhD FRCR · Castle Hill Hospital, Hull

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-16
Primary Completion
2024-05-31
Completion
2024-05-31
FDA Drug
Yes

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05744128 on ClinicalTrials.gov